UNSPSC 51112902: Temozolomide

This classification denotes a triazene compound and gonadotropin releasing hormone inhibitor with the molecular formula C6H6N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YF1K15M17Y, chemically known as 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide but more generally known as temozolomide, which bears US NIH Compound Identifier 5394. European Medicines Agency schedules Temozolomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10889MIG.

UNSPSC 51112902 Temozolomide is a Commodity code covering pharmaceutical procurement for cancer treatment medication. State and local governments buy temozolomide primarily through health and human services agencies managing pharmacy benefit programs for state employees, retirees, and Medicaid beneficiaries. The recent activity under this code reflects a shift toward direct-to-manufacturer procurement models as jurisdictions seek to reduce costs and improve supply chain efficiency outside traditional pharmacy benefit manager (PBM), group purchasing organization (GPO), and wholesaler arrangements. State health and human services commissions are the primary issuing bodies, typically procuring on behalf of self-insured employee health plans, retiree programs, and Medicaid managed care operations.

The Texas Health and Human Services Commission issued Request for Information (RFI) HHS0017013 in March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with responses due April 3, 2026. The RFI solicited information from potential vendors regarding direct contracting capacity, experience with self-insured employers and government health plans, flexibility with negotiated net pricing models, and ability to implement value-based or outcomes-based agreements. This exploratory phase precedes a formal Request for Proposal (RFP) that will establish specific financial and temporal parameters. No award value or budget has been identified in the RFI materials, as the state is conducting foundational market intelligence before committing to contract amounts or durations.